If you wish to serve as lead plaintiff, you must move the Court no later than 60 days from the date of this notice (May 26, 2007). If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact plaintiff’s counsel, Alan Sparer, Marc Haber or James Nabwangu of The Law Offices of Alan W. Sparer at 415-217-7300 or via e-mail at info @ sparerlaw.com. If you are a member of this class, you can view a copy of the complaint as filed at www.sparerlaw.com. Any member of the purported class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

The Complaint alleges that within weeks of OrthoClear’s launch, Align Technology—OrthoClear’s sole competitor—filed multiple law suits alleging OrthoClear had stolen Align’s intellectual property, infringed its patents and used its propriety customer information without consent. OrthoClear Holdings raised $10-20 million from investors in private placements of Class A, B, and C Preferred Convertible Shares, while assuring potential investors that Align’s claims and lawsuits were wholly without merit.

On the eve of first trial between Align and OrthoClear (and without warning) OrthoClear abandoned its defense of the Align litigation, announcing that it had entered into a settlement that required it to assign its intellectual property to Align and exit the orthodontic aligner business in return for a payment of only $20 million. In a letter to shareholders in October 2006, OrthoClear admitted for the first time that it was likely to lose the litigation with Align, and further acknowledged that the costs of prosecuting and defending the Align lawsuits were prohibitive.

The Complaint alleges that false and fraudulent statements made in OrthoClear’s Purchase Agreements, press releases, and oral presentations assured that the operation of OrthoClear’s business did not infringe any patent or other proprietary right of Align. The Complaint further alleges that, instead of using the $20 million for the benefit of all its shareholders, OrthoClear unlawfully refunded all or a significant portion of the $10 million investment made by 3i. It is alleged this distribution violated OrthoClear’s own Memorandum of Association and applicable laws governing corporate distributions. It is also alleged this action constituted a breach of fiduciary duty by OrthoClear’s current and former directors.

Contact:
Alan Sparer
415-217-7300